gene therapy

R&D

Will cell and gene therapies disrupt reimbursement?

Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people with rare diseases and cancers – but they could also mean healthcare systems

News

Gene therapy biotech shares sink on inconclusive trial resul...

Shares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results in early clinical trials.

Digital

Deep Dive: Disruptive Technologies

In the first issue of Deep Dive for 2019, we look at disruptive technologies in pharma, how they're changing medicine, research and development, and healthcare, and how the

News

Nearly 300 gene and cell therapies in development - report

Pharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting review by the FDA, according to a new report from US trade body PhRMA

News

Red blood cells moving in blood vessels with depth of field.

FDA gives go-ahead for CRISPR-based sickle cell disease tria...

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can go ahead, after the FDA lifted a hold on a review.

Events